You are here

diabetes

Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Fierce Pharma

Teva Pharmaceutical

Flag link:

3 Top Diabetes Stocks to Watch in March

3 Top Diabetes Stocks to Watch in March

Yahoo/Motley Fool

Flag link:

How Much Difference Will Eli Lilly's Half-Price Insulin Make?

How Much Difference Will Eli Lilly's Half-Price Insulin Make?

NPR

Flag link:

Livongo preps for $1B IPO

Livongo preps for $1B IPO

Drug Delivery Business News

Flag link:

Senators seek changes to FDA guidance to speed entry of insulin biosimilars

Senators seek changes to FDA guidance to speed entry of insulin biosimilars

Endpoints

Flag link:

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

Endpoints

Flag link:

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

Endpoints

clinical trials

Flag link:

U.S. Senators launch bipartisan probe into rising insulin prices

U.S. Senators launch bipartisan probe into rising insulin prices

Yahoo/Reuters

Flag link:

Abbott touts real-world data for FreeStyle Libre glucose monitor

Abbott touts real-world data for FreeStyle Libre glucose monitor

Drug Delivery Business News

real world evidence

real world data

FreeStyle Libre

blood glucose monitoring

Flag link:

Abbott, Novo Nordisk ink deal for digital diabetes tools

Abbott, Novo Nordisk ink deal for digital diabetes tools

Drug Delivery Business News

FreeStyle Libra

connected insulin pen

Flag link:

Another Significant Milestone in the Diabetes Space

Another Significant Milestone in the Diabetes Space

Medical Devices and Diagnostics Industry

Tandem Diabetes

alternate controller enabled infusion pumps

Flag link:

‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around

‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around

Stat

Flag link:

3 Top Diabetes Stocks to Watch in February

3 Top Diabetes Stocks to Watch in February

Motley Fool

Lexicon Pharmaceuticals

Tandem Diabetes

Flag link:

An oral insulin delivery system inspired by tortoises

An oral insulin delivery system inspired by tortoises

Fierce Biotech

Brigham and Women's

Flag link:

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

Fierce Pharma

Flag link:

Zafgen has something to cheer as diabetes drug makes the cut in PhII study, quelling cardio safety fears

Zafgen has something to cheer as diabetes drug makes the cut in PhII study, quelling cardio safety fears

Endpoints

clinical trials

Flag link:

How a 'regulatory dead zone' may be holding up copycat insulin

How a 'regulatory dead zone' may be holding up copycat insulin

Biopharma Dive

Flag link:

Novo Nordisk’s first diabetes innovation challenge winners head to the lab

Novo Nordisk’s first diabetes innovation challenge winners head to the lab

Fierce Pharma

Flag link:

Diabetes tech execs talk patient-centric design, device development & trust

Diabetes tech execs talk patient-centric design, device development & trust

Mass Device

clinical trials

Flag link:

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Fierce Pharma

Boehringer Ingelheim

Flag link:

Pages